PMA device
Rx Acculink Carotid Stent System
Abbott Vascular · Stent, Carotid (NIM, Class III) · First FDA decision Feb 21, 2008, newest Mar 4, 2016Carotid artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
8
Naming "Rx Acculink"
MAUDE reports
172
Brand "Rx Acculink", since 2015
PubMed studies
0
Mentioning "Rx Acculink"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Rx Acculink Carotid Stent System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- RX ACCULINK CAROTID STENT SYSTEMPMA supplement
P040012-S056 · Decided Mar 4, 2016 · 60 days after receipt · Normal 180 Day Track No User Fee
Device type: Stent, carotid (NIM) · Cardiology
5 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Carotid Artery Stenting in Post-Approval StudiesNational analysisReview closedCAG-00259NUpdated Sep 17, 2026
- Carotid Artery StentingNational analysisReview closedCAG-00085RUpdated Sep 17, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Rx Acculink", any status and sponsor, newest update first.
- The SIBERIA Trial (Acculink™ Versus CGuard™)Pivotal-lookingCompleted
Meshalkin Research Institute of Pathology of CirculationResearch network
NCT03488199 · 100 participants · Start Sep 11, 2017 · Primary completion Feb 11, 2021
Device: Stent Acculink ™; CGuardTM™ · For: Patients With Aterosclerotic Carotid Stenosis; Symptomatic Patients (Stenosis > 50%); Asymptomatic Patients (Stenosis ≥80%)
Sites: Novosibirsk, Russia
7 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Rx Acculink", and for the whole product code for context.
This brand
172 reports: 107 malfunction, 56 injury, 9 death
Whole product code NIM
2,799 reports: 1,699 malfunction, 994 injury, 98 death
Newest reports for this brand
2024168-2026-03737 · Received Sep 29, 2026 · Event dated Sep 4, 2026
Device type: Stent, Carotid (NIM)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Aneurysm; Syncope/Fainting
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0337-2011 · Started Sep 10, 2010 · Posted by FDA Nov 10, 2010
Reason given: The recall was initiated because Abbott vascular has discovered through internal testing that the affected lots may not meet the firm's quality specifications for catheter shaft tensile strength. If the affected device is used it may result in acute stent deployment difficulties and subsequent intervention.
Cause as FDA categorized it: Pending · Device type: Stent, Carotid (NIM)
3 more recall records with a free account
Published research
The most relevant PubMed records for "Rx Acculink"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code NIM.
- XACT® Carotid Stent SystemAbbott Vascular, Inc. · PMA 2025
- ENROUTE Transcarotid Stent SystemBoston Scientific Corporation · PMA 2023
- Carotid Wallstent Monorail EndoprosthesisBoston Scientific Corp · PMA 2024
- Acculink Carotid Stent System and Rx Acculink Carotid Stent SystemAbbott Vascular · PMA 2017
- Roadsaver/CASPER Carotid Stent DeviceMicroVention, Inc. · PMA 2025
- Cartoid Wallstent Monorail EndoprosthesisBoston Scientific Corp · PMA 2012
- Protege Gps & Protege Rx Carotid Stent SystemsMedtronic Vascular, Inc. · PMA 2011
- Cordis Precise Nitinol StentCordis US Corporation · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.